

**Developing peptide based capture agents
for diagnostics and therapeutics**

Thesis by
Arundhati Nag

In Partial Fulfillment of the Requirements for the degree
of
Doctor of Philosophy



CALIFORNIA INSTITUTE OF TECHNOLOGY
Pasadena, California
2013
(Defended May 16, 2013)

© [2013]

[Arundhati Nag]

All Rights Reserved

DEDICATIONS

I dedicate this dissertation to my father, friend, philosopher and guide, Mr. Dilip Kumar Nag

ACKNOWLEDGEMENTS

I want to thank my advisor, Professor J. Heath for giving me an opportunity to work with him. I have always been inspired by Jim's vision of science and his ability to define scientific challenges in new and unconventional ways. Throughout my graduate research, Jim has been very supportive, allowing me to define and evolve my own projects. I would also like to thank the members of my thesis committee, Professor David Tirrell, Professor Robert H. Grubbs, and Professor Long Cai for their support and advice.

I immensely enjoyed interacting with Professor Barry Sharpless, Professor Valery Fokin, Dr. Suresh Pitram and Dr. Jason Hein of the Scripps Research Institute, San Diego, when we were developing the capture agent technology and would like to thank them for their valuable advice. I have also enjoyed long and successful collaboration with Dr. Su Seong Lee, Dr. Jaehong Lim, Dr. Junhoe Cha, Sylvia Tan, Shi Yun Yeo, and Yiran Zheng from the Institute of Bioengineering and Nanotechnology, Singapore. I want to specially thank Dr. Su Seong Lee for his support and advice.

I would like to thank the current members of my subgroup, Kaycie M. Butler, Jessica Pfeilsticker, Ryan Henning, Joeseeph Varghese, Blake Farrow, Dr. Aiko Umeda, Baoqing Zhou and Jingxin Liang for their feedback on my research. I started my graduate life working with Dr. Heather Agnew and Dr. Rosemary Rohde. Heather and Rose have been good mentors, answering my every question and training me. Dr. Steven Millward helped me with details of biochemical experiments. I would like to thank Heather, Rose and Steve for the guidance they provided. All the other graduate students, postdoctoral scholars, and staff in the Heath lab have also befriended and guided me.

I have been lucky to work with several exceptional undergraduate students, Abdul Ahad Tariq, Mary Beth Yu and Belen Alvarez during my years at Caltech. Their work has been instrumental in finishing my dissertation.

During my research I have used resources from other research laboratories as well as Caltech central facilities. I thank Dr. Jost Vielmetter of the Protein Expression Center and Professors David A. Tirrell for the use of the SPR. I thank Professor David A. Baltimore for ready access to the ELISA plate reader. I thank Dr. Mona Shahgholi for assistance with MALDI-MS measurements. I thank Professor Carl S. Parker for the unconditional lab access he has provided and thank the Caltech Protein/Peptide Micro Analytical Laboratory for acquiring ESI-TOF spectra.

I would like to thank the Institute for Collaborative Biotechnologies, the Army Research Office, the National Cancer Institute and the Bill and Melinda Gates Foundation for funding my research.

Finally, I would like to acknowledge my family for the love and support they have provided. Though my father is no longer with us, he continues to be a source of inspiration to me. Ever since my childhood, I have been inspired by my mother's determination and self-reliance. My brother has always nurtured me and pushed me to attain my life's ambition. My husband, Dr. Samir Das, is also my lab mate and co-author of a major portion of my dissertation work. Samir and I make a great team, and I hope we continue to collaborate in the future.

ABSTRACT

Iterative in situ click chemistry (IISCC) is a robust general technology for development of high throughput, inexpensive protein detection agents. In IISCC, the target protein acts as a template and catalyst, and assembles its own ligand from modular blocks of peptides. This process of ligand discovery is iterated to add peptide arms to develop a multivalent ligand with increased affinity and selectivity. The peptide based protein capture agents (PCC) should ideally have the same degree of selectivity and specificity as a monoclonal antibody, along with improved chemical stability. We had previously reported developing a PCC agent against bovine carbonic anhydrase II (bCAII) that could replace a polyclonal antibody. To further enhance the affinity or specificity of the PCC agent, I explore branching the peptide arms to develop branched PCC agents against bCAII. The developed branched capture agents have two to three fold higher affinities for the target protein.

In the second part of my thesis, I describe the epitope targeting strategy, a strategy for directing the development of a peptide ligand against specific region or fragment of the protein. The strategy is successfully demonstrated by developing PCC agents with low nanomolar binding affinities that target the C-terminal hydrophobic motif of Akt2 kinase. One of the developed triligands inhibits the kinase activity of Akt. This suggests that, if targeted against the right epitope, the PCC agents can also influence the functional properties of the protein. The exquisite control of the epitope targeting strategy is further demonstrated by developing a cyclic ligand against Akt2. The cyclic ligand acts as an inhibitor by itself, without any iteration of the ligand discovery process. The epitope targeting strategy is a cornerstone of the IISCC technology and opens up new opportunities, leading to the development of protein detection agents and of modulators of protein functions.

Table of Contents

DEDICATIONS	iii
ACKNOWLEDGEMENTS	iv
ABSTRACT	vi
List of Tables	xi
List of Figures.....	xiii
Chapter 1: Introduction	17
1.1 Introduction.....	18
Chapter 2: Development of branched capture agents against bovine carbonic anhydrase	
II.....	27
2.1 Introduction.....	28
2.2 Materials and Methods	29
2.2.1 Materials	29
2.2.2 Methods	29
2.2.2.1 Synthesis of azide and alkyne containing artificial amino acids	29
2.2.2.2 Procedure for peptide synthesis	33
2.2.2.3 Measurement of the Relative Hydrophobicity Coefficients of amino acids...	35
2.2.2.4 Construction of Peptide Libraries	35
2.2.2.5 Screening procedures.....	37
2.2.2.6 Dot blots.....	46
2.2.2.7 ELISA with PCC agent as capture agent.....	47
2.3 Results and discussion	47

2.3.1	Development of branched biligand using randomized azide library	48
2.3.2	Substitution of amino acid in linear ligand to developed branched biligand	53
2.3.3	Branched triligand development with substituted biligand	58
2.3.4	Development of branched triligands using biligand anchor isolated through screens	61
2.3.5	Characteristics of developed capture agents	64
2.3.6	Substitution of triazole linkage by triazole mimic	66
2.4	Conclusions	70

Chapter 3: Epitope targeting strategy: developing capture agents targeted against C

terminal hydrophobic motif of the Akt2 protein.....	73
3.1	Introduction..... 74
3.2	Materials and methods..... 76
3.2.1	Materials 76
3.2.2	Methods 77
3.2.2.1	Synthesis of phosphate binding dinuclear metal ligand complex..... 77
3.2.2.2	Verification of binding of Zn ₂ L-Az4-PEG ₂ -Biotin to phospho-amino acids and a phosphate containing peptide 78
3.2.2.3	Peptide library Synthesis 81
3.2.2.4	Screening with One Bead One Compound (OBOC) peptide library..... 81
3.2.2.5	Bulk peptide synthesis 89
3.3	Results and discussion 101
3.3.1	Synthesis of the dinuclear zinc chelator Zn ₂ L-Az4-PEG ₂ -Biotin and verification of its binding to phospho amino acids and phosphopeptide..... 101
3.3.2	Modification of peptide fragment of Akt2..... 102
3.3.3	Identification of a 1 ^o ligand targeted against Akt2 C terminal fragment..... 104

3.3.4	Identification of a biligand targeted against Akt2 C terminal fragment	105
3.3.5	Development of Triligands against full length Akt2 protein	106
3.4	Conclusion	107
Chapter 4: Characterization of protein capture agents developed against Akt2.....		111
4.1	Introduction.....	112
4.2	Materials and Methods	112
4.2.1	Materials	112
4.2.2	Methods	113
4.2.2.1	Peptide synthesis.....	113
4.2.2.2	ELISA for <i>mono-L</i> and <i>bi-L</i>	113
4.2.2.3	ELISA for <i>N-term-tri-L</i> and <i>C-term-tri-L</i>	114
4.2.2.4	OVCAR3 lysate pulldown assay	114
4.2.2.5	Non-radioactive kinase assay to evaluate effect of ligands on Akt2 kinase activity	115
4.2.2.6	Epitope Targeting Selectivity Assay	117
4.2.2.7	Protein Isoform Selectivity Assay	117
4.2.2.8	Measurement of binding affinity of N-term-tri-L and N-term-tri-L-dimer by Surface Plasmon Resonance	117
4.3	Results and discussion	118
4.3.1	Characterics of PCC ligands developed against Akt2	118
4.3.2	Inhibitory Characteristics of the Akt2 Capture Agents	123
4.4	Conclusions.....	126
Chapter 5: Development of CuAAC cyclized one bead one compound peptide libraries and their application in the epitope targeting strategy.....		128
5.1	Introduction.....	129

5.2	Materials and Methods	130
5.2.1	Materials	130
5.2.2	Methods	130
5.2.2.1	Synthesis of randomized peptide library and on bead cyclization.....	130
5.2.2.2	Synthesis of scrambled phospho-epitope and target phospho-epitope	133
5.2.2.3	IR spectra	133
5.2.2.4	Screening cyclic OBOC library with peptide epitope	133
5.2.2.5	ELISA for cyclic peptide Cy(yytytTz4) against full length Akt2 protein	134
5.2.2.6	Non-radioactive kinase assay to evaluate effect of ligands on Akt2 kinase activity.....	135
5.3	Results and discussion	136
5.3.1	Verification of on bead cyclization by Edman Peptide Sequencing.....	136
5.3.2	IR verification of on bead cyclized peptide formation by CuAAC reaction	137
5.3.3	Using on bead cyclic peptide library for ligand discovery	138
5.3.4	Determination of best cyclic binder to the target Akt2 C terminal fragment	139
5.3.5	Effect of cyclization on binding specificity	139
5.3.6	Effect of ring size on binding	140
5.3.7	Characterization of the cyclic ligand Cy(YYTYT-Tz4).....	142
5.3.8	Effect of cyclic monoligand on Akt2 kinase activity	143
5.3.9	Optimization of monoligand anchor	144
5.4	Conclusion	147

List of Tables

Chapter 2

Table 2.1: One Bead One Compound (OBOC) peptide libraries used in screens.	36
Table 2.2: Summary of screens for the development of branched PCC agents for bovine carbonic anhydrase II.....	37
Table 2.3: Hit sequences from the first biligand screen BB1.	40
Table 2.4: Hit sequences from the second generation biligand screen BB2.....	41
Table 2.5: Hit sequences from the third generation biligand screen BB3.	42
Table 2.6: Hit sequences from the first generation triligand screen TRI1	43
Table 2.7: Hit sequences from the second generation triligand screen TRI2	45
Table 2.8: Hit sequences from the first generation screen TRI3 using the product screening method.....	46
Table 2.9: Table summarizing the limits of detection (L.O.D) of the bovine carbonic anhydrase II protein using the developed multiligands as detection agents.	65

Chapter 3

Table 3.1: Summary of libraries used in screens against the Akt2 protein.....	81
Table 3.2: Sequences of hits from the monoligand (<i>mono-L</i>) screen.	82
Table 3.3: Hit sequences from the biligand (<i>bi-L</i>) screen with 25 nM target peptide.	84
Table 3.4 Hit sequences for biligand screen with 10 nM target peptide.....	84
Table 3.5: Hit sequences for N terminal triligand (<i>N-term-tri-L</i>) screen.....	87
Table 3.6: Elimination of peptide binders to the detection antibody for the N terminal triligand (<i>N-term-tri-L</i>) screen.....	88
Table 3.7: Hit sequences from the C terminal triligand (<i>C-term-tri-L</i>) screen.....	89

Chapter 5

Table 5.1 One Bead One Compound (OBOC) cyclic peptide libraries used in screens	132
Table 5.2: List of sequences obtained from screen against target epitope using cyclic library C.	134

List of Figures

Chapter 2

Figure 2.1: Synthesis of unnatural amino acids containing PEGylated azide side chains.....	29
Figure 2.2: Modification of D-phenyl alanine with an azido/acetylene group to synthesize amino acids 30 -33.	31
Figure 2.3: Molecular structures of the reported monoligand 36 and the monoligand anchor 37 used in the branched biligand screen.	50
Figure 2.4: Schematic representation of target screen against bovine carbonic anhydrase II using OBOC library with multiple azides for developing a branched biligand.....	50
Figure 2.5: Motifs obtained by screening against bovine carbonic anhydrase II in presence of monoligand anchor peptide 37.	51
Figure 2.6: Molecular structures of branched biligands 38 and 39 and biligand anchor 40.	52
Figure 2.7: Synthesized artificial amino acids with side chains containing azide or alkyne functional side chains.	54
Figure 2.8: Comparison of Relative Hydrophobicity Coefficients (RHC) of natural amino acids with those of synthesized artificial amino acids containing azide or alkyne functional group in the side chain.....	55
Figure 2.9: Amino acid substitution in the linear biligand to develop branched biligands.	56
Figure 2.10: SPR response sensograms of the branched biligands developed by amino acid substitution of the linear biligand.....	57
Figure 2.11: Schematic representation of the in situ click target screens TRI1 and TRI2 for developing branched triligand.....	58
Figure 2.12: Branched triligand development through two generation target screen starting from a comprehensive randomized library.	59

Figure 2.13: Molecular structures of the linear triligand 44 and the three branched triligands 45, 46 and 47 obtained through the target screening process using modified biligand 42 and bovine carbonic anhydrase II protein.....	60
Figure 2.14: Scheme for in situ click product screen TRI3 for development of branched triligand.	62
Figure 2.15: Molecular structures of branched triligands developed through product screen against the bovine carbonic anhydrase II.	63
Figure 2.16: Biligands and triligands used as detection agents for bCAII.....	65
Figure 2.17: ELISA demonstrating relative binding affinities of biligands and triligands.....	66
Figure 2.18: Molecular structure comparison of 1,5 disubstituted triazole linked biligand and its mimic.....	68
Figure 2.19: Comparison of the binding affinities of 1,4 and 1,5 disubstituted regioisomers of biligands to carbonic anhydrase II protein.	69

Chapter 3

Figure 3.1: Synthesis of dinuclear Zn chelator Zn ₂ L-Az4-PEG ₂ -Biotin.....	79
Figure 3.2: Evidence of binding of dinuclear zinc chelator to phospho amino acids and phospho peptide.....	80
Figure 3.3: Sequence of the phospho peptide used as target epitope.....	90
Figure 3.4: Synthesis of the intermediate S1 for the bulk synthesis of the monoligand peptide <i>mono-L</i>	91
Figure 3.5: Structure of the monoligand peptide <i>mono-L</i> developed against the target peptide. ..	91
Figure 3.6: Synthesis of the zinc chelator - monoligand complex <i>compound 4</i> used in biligand screen of Akt2.	93
Figure 3.7: Synthesis of intermediate S3 for bulk synthesis of the biligand <i>bi-L</i> , biligand anchor <i>anchor-3C</i> and the triligand <i>C-term-tri-L</i>	94

Figure 3.8: Structure of the biligand <i>bi-L</i> isolated in the screen against the target peptide.....	94
Figure 3.9: Synthesis of intermediate S4 for the bulk synthesis of the biligand anchor <i>anchor-3N</i> and the triligand <i>N-term-tri-L</i>	96
Figure 3.10: Structure of biligand anchor peptides <i>Anchor-3N</i> and <i>Anchor-3C</i>	97
Figure 3.11: Molecular structure of the triligand <i>N-term-tri-L</i>	98
Figure 3.12: Synthesis of intermediate compound S5 for bulk synthesis of the triligand <i>N-term-tri-L-dimer</i>	99
Figure 3.13: Molecular structure of the triligand <i>N-term-tri-dimer</i>	100
Figure 3.14: Molecular structure of the triligand <i>C-term-tri-L</i>	101
Figure 3.15: Complex-1 is formed by the reaction of dinuclear zinc complex with the phosphopeptide epitope.	103
Figure 3.16: Screening strategy for developing a capture agent targeting the C terminal hydrophobic motif of the Akt2 protein.	105
Figure 3.17: Scheme describing triligand screens using <i>anchor-3N</i> and <i>anchor-3C</i>	107

Chapter 4

Figure 4.1: Immunoprecipitation and Western Blot assays showing the performance of the various PCC Agents.	120
Figure 4.2: ELISA assays demonstrating use of PCC Agents.	120
Figure 4.3: Epitope specificity assay.	121
Figure 4.4: Selectivity of triligands for the full length Akt isoform proteins.	121
Figure 4.5: SPR measurements of triligands.....	122
Figure 4.6: Influence of the PCC Agents on the enzymatic activity of the Akt2 kinase.	125

Chapter 5

Figure 5.1: Peptide cyclization on bead by the Cu catalyzed Azide Alkyne Cycloaddition (CuAAC) reaction.	131
---	-----

Figure 5.2: Cyclic peptide ligands isolated by screening against target peptide epitope.....	136
Figure 5.3: IR spectra of linear peptide L-Pra-VFAKV-L-Az4 and the cyclic peptide Cy(VFAKVTz4).	138
Figure 5.4: Selectivity of the cyclic peptide Cy(YYTYT-Tz4) for the target peptide.....	139
Figure 5.5: The cyclized ligand Cy(YYTYT-Tz4) shows significant binding to the epitope compared to its linear version L-Pra-YYTYT-L-Az4.	140
Figure 5.6: Ring size affects cyclization efficiency.	141
Figure 5.7: Effect of ring size on epitope selectivity.	141
Figure 5.8: Determination of binding affinity of cyclic ligand Cy(YYTYT-Tz4) for Akt2 protein	142
Figure 5.9: Cy(YYTYT-Tz4) is selective for the Akt2 protein over the Akt1 and Akt3 proteins.	143
Figure 5.10: Cyclic ligand Cy(YYTYT-Tz4) inhibits Akt kinase activity.	143
Figure 5.11: Monoligand anchor candidate peptides developed for biligand screen.....	145
Figure 5.12: Comparison of HPLC traces to determine best monoligand anchor candidate.....	146